SCHEMBL25255165

SCHEMBL25255165

COc1ccc(-c2nc(N)c3nnnn3c2-c2ccc3nccc(C)c3c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 2/20 0.40
▸ SYK P43405 1/20 0.38
▸ MAPT P10636 4/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ HCRTR1 O43613 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ SENP8 Q96LD8 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SENP6 Q9GZR1 1/20 0.37
▸ ADORA3 P0DMS8 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30359483 1.00 MAP4K4 (0.40) MAP4K4SYKMAPTKDM4EALDH1A1
SCHEMBL25205150 0.89 MAPK1 (0.41) MAP4K4MAPTKDM4EALDH1A1HPGD
SCHEMBL30359478 0.88 MAPK14 (0.40) MAP4K4MAPTKDM4EALDH1A1HPGD
SCHEMBL30359474 0.88 KDM4E (0.38) MAP4K4MAPTKDM4EALDH1A1HPGD
SCHEMBL25206143 0.88 KDM4E (0.38) MAP4K4MAPTKDM4EALDH1A1HPGD
SCHEMBL25206204 0.88 MAPK14 (0.40) MAP4K4MAPTKDM4EALDH1A1HPGD
SCHEMBL30359464 0.86 MAP4K4 (0.39) MAP4K4MAPTKDM4EALDH1A1HPGD
SCHEMBL25235560 0.86 MAP4K4 (0.39) MAP4K4MAPTKDM4EALDH1A1HPGD
SCHEMBL25251378 0.85 KDR (0.41) MAP4K4MAPTKDM4EALDH1A1HPGD
SCHEMBL30359460 0.85 KDR (0.41) MAP4K4MAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122203-A1 ADENOSINE RECEPTOR ANTAGONISTS CROSSIGNAL THERAPEUTICS, INC. 2025-04-17 — — US claimed
US-12065444-B2 Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists CROSSIGNAL THERAPEUTICS, INC. (US) 2024-08-20 — — US claimed
WO-2023091604-A1 ADENOSINE RECEPTOR ANTAGONISTS CROSSIGNAL THERAPEUTICS, INC. (US) 2023-05-25 — — WO claimed
US-20230159541-A1 ADENOSINE RECEPTOR ANTAGONISTS CROSSIGNAL THERAPEUTICS, INC. 2023-05-25 — — US claimed
US-20250122203-A1 ADENOSINE RECEPTOR ANTAGONISTS CROSSIGNAL THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12065444-B2 Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists CROSSIGNAL THERAPEUTICS, INC. (US) 2024-08-20 — — US disclosed
WO-2023091604-A1 ADENOSINE RECEPTOR ANTAGONISTS CROSSIGNAL THERAPEUTICS, INC. (US) 2023-05-25 — — WO disclosed
US-20230159541-A1 ADENOSINE RECEPTOR ANTAGONISTS CROSSIGNAL THERAPEUTICS, INC. 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122203-A1 ADENOSINE RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 MAP4K4 3318/4885SYK 4525/4885MAPT 4542/4885
US-20230159541-A1 ADENOSINE RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 MAP4K4 3318/4885SYK 4525/4885MAPT 4542/4885
US-12065444-B2 Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists ADORA2A, ADORA1, P2RX5 MAP4K4 3222/4885SYK 3002/4885MAPT 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback